NASDAQ: ENVBEnveric Biosciences Inc Stock
$1.32-0.04 (-2.94%)
Updated Apr 30, 2025
ENVB Price
$1.32
Fair Value Price
N/A
Market Cap
$3.26M
52 Week Low
$1.01
52 Week High
$15.45
P/E
-0.07x
P/B
2.05x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$9.57M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.94
Operating Cash Flow
-$8M
Beta
1.58
Next Earnings
May 13, 2025
Ex-Dividend
N/A
Next Dividend
N/A
ENVB Overview
Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ENVB's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ENVB
Ranked#329 of 462
Ranked#329 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $3.07 | A | |
| $8.24 | A | |
| $24.29 | A |
Be the first to know about important ENVB news, forecast changes, insider trades & much more!
ENVB News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ENVB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ENVB is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ENVB is good value based on its book value relative to its share price (2.05x), compared to the US Biotechnology industry average (4.45x)
P/B vs Industry Valuation
ENVB is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ENVB due diligence checks available for Premium users.
Valuation
ENVB fair value
Fair Value of ENVB stock based on Discounted Cash Flow (DCF)
Price
$1.32
Fair Value
$1.06
Overvalued by
24.56%
ENVB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ENVB price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.07x
Industry
-162.28x
Market
29.18x
ENVB price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.05x
Industry
4.45x
ENVB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ENVB's financial health
Profit margin
Revenue
$0.0
Net Income
-$3.2M
Profit Margin
0%
ENVB's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$3.1M
Liabilities
$1.5M
Debt to equity
0.94
ENVB's short-term assets ($2.73M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ENVB's short-term assets ($2.73M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ENVB's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ENVB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.3M
Investing
$0.0
Financing
$463.4k
ENVB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ENVB vs Biotech Stocks
Enveric Biosciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.